Lele Song1,2, Jia Jia3,4, Haotian Yu3, Xiumei Peng5,6, Wenhua Xiao6, Yuan Gong7, Guangpeng Zhou8, Xiaoliang Han8, Yuemin Li9. 1. Department of Radiotherapy, The Chinese PLA 309th Hospital, No. 17, Heishanhu Road, Haidian district, Beijing, People's Republic of China. songlele@sina.com. 2. BioChain (Beijing) Science and Technology, Inc, Beijing, People's Republic of China. songlele@sina.com. 3. Department of Radiotherapy, The Chinese PLA 309th Hospital, No. 17, Heishanhu Road, Haidian district, Beijing, People's Republic of China. 4. Department of Graduate, Hebei North University, Zhangjiakou, Hebei, People's Republic of China. 5. Medical School of Chinese PLA and Chinese PLA General Hospital, Beijing, People's Republic of China. 6. Department of Oncology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, People's Republic of China. 7. Department of Gastroenterology, The Chinese PLA General Hospital, Beijing, People's Republic of China. 8. BioChain (Beijing) Science and Technology, Inc, Beijing, People's Republic of China. 9. Department of Radiotherapy, The Chinese PLA 309th Hospital, No. 17, Heishanhu Road, Haidian district, Beijing, People's Republic of China. liyuemin224@sina.com.
Abstract
PURPOSE: This study aims to examine the influence of algorithm and subject-related factors, including cancer stage, age, sex, and cancer location, on the performance of the SEPT9 gene methylation test, an assay approved by the US FDA for colorectal cancer (CRC) screening. METHODS: A total of 1225 subjects were recruited in this opportunistic screening study, including 388 CRC patients, 139 subjects with adenoma, 108 subjects with hyperplastic polyps, and 590 subjects with no evidence of disease (NED). Epi proColon 2.0 CE assay was used to examine the blood level of SEPT9 gene methylation. RESULTS: It was found that tests using 1/3 algorithm exhibited higher detection rate than those using the 2/3 algorithm for CRC, adenoma, hyperplastic polyps, while the false positive rate in subjects with NED was also higher with 1/3 algorithm. The positive detection rate (PDR) of the assay for stage 0 and I CRC were lower than later stages (Stage II, III and IV). Interestingly, the normal subjects above 60 years old exhibited significantly higher PDR than subjects from younger groups, while no significant change in PDR was observed among age groups in CRC patients. Furthermore, no difference in the PDR for CRC was found between male and female, and the PDR for CRC at various colorectal locations were essentially identical. CONCLUSIONS: Algorithm, cancer stage and age are factors affecting the detection rate of the SEPT9 assay, while sex and cancer location appeared to have no influence on its performance.
PURPOSE: This study aims to examine the influence of algorithm and subject-related factors, including cancer stage, age, sex, and cancer location, on the performance of the SEPT9 gene methylation test, an assay approved by the US FDA for colorectal cancer (CRC) screening. METHODS: A total of 1225 subjects were recruited in this opportunistic screening study, including 388 CRC patients, 139 subjects with adenoma, 108 subjects with hyperplastic polyps, and 590 subjects with no evidence of disease (NED). Epi proColon 2.0 CE assay was used to examine the blood level of SEPT9 gene methylation. RESULTS: It was found that tests using 1/3 algorithm exhibited higher detection rate than those using the 2/3 algorithm for CRC, adenoma, hyperplastic polyps, while the false positive rate in subjects with NED was also higher with 1/3 algorithm. The positive detection rate (PDR) of the assay for stage 0 and I CRC were lower than later stages (Stage II, III and IV). Interestingly, the normal subjects above 60 years old exhibited significantly higher PDR than subjects from younger groups, while no significant change in PDR was observed among age groups in CRC patients. Furthermore, no difference in the PDR for CRC was found between male and female, and the PDR for CRC at various colorectal locations were essentially identical. CONCLUSIONS: Algorithm, cancer stage and age are factors affecting the detection rate of the SEPT9 assay, while sex and cancer location appeared to have no influence on its performance.
Authors: Eline H Schreuders; Arlinda Ruco; Linda Rabeneck; Robert E Schoen; Joseph J Y Sung; Graeme P Young; Ernst J Kuipers Journal: Gut Date: 2015-06-03 Impact factor: 23.059
Authors: Andrew E Teschendorff; Usha Menon; Aleksandra Gentry-Maharaj; Susan J Ramus; Daniel J Weisenberger; Hui Shen; Mihaela Campan; Houtan Noushmehr; Christopher G Bell; A Peter Maxwell; David A Savage; Elisabeth Mueller-Holzner; Christian Marth; Gabrijela Kocjan; Simon A Gayther; Allison Jones; Stephan Beck; Wolfgang Wagner; Peter W Laird; Ian J Jacobs; Martin Widschwendter Journal: Genome Res Date: 2010-03-10 Impact factor: 9.043
Authors: David A Johnson; Robert L Barclay; Klaus Mergener; Gunter Weiss; Thomas König; Jürgen Beck; Nicholas T Potter Journal: PLoS One Date: 2014-06-05 Impact factor: 3.240
Authors: Kinga Tóth; Ferenc Sipos; Alexandra Kalmár; Arpád V Patai; Barnabás Wichmann; Robert Stoehr; Henriette Golcher; Vera Schellerer; Zsolt Tulassay; Béla Molnár Journal: PLoS One Date: 2012-09-25 Impact factor: 3.240
Authors: Alexander Semaan; Anne van Ellen; Sebastian Meller; Dominik Bergheim; Vittorio Branchi; Philipp Lingohr; Diane Goltz; Jörg C Kalff; Glen Kristiansen; Hanno Matthaei; Dimitrios Pantelis; Dimo Dietrich Journal: Clin Epigenetics Date: 2016-09-20 Impact factor: 6.551
Authors: Robert W Haile; Henry T Lynch; Megan P Hitchins; Ingrid P Vogelaar; Kevin Brennan; Sigurdis Haraldsdottir; Nianmin Zhou; Brock Martin; Rocio Alvarez; Xiaopu Yuan; Sungjin Kim; Maha Guindi; Andrew E Hendifar; Matthew F Kalady; Jennifer DeVecchio; James M Church; Albert de la Chapelle; Heather Hampel; Rachel Pearlman; Maria Christensen; Carrie Snyder; Stephen J Lanspa Journal: BMJ Open Gastroenterol Date: 2019-05-28
Authors: Sander Bach; Nina R Sluiter; Jamie J Beagan; Joost M Mekke; Johannes C F Ket; Nicole C T van Grieken; Renske D M Steenbergen; Bauke Ylstra; Geert Kazemier; Jurriaan B Tuynman Journal: JNCI Cancer Spectr Date: 2019-06-19
Authors: Luka de Vos; Heidrun Gevensleben; Andreas Schröck; Alina Franzen; Glen Kristiansen; Friedrich Bootz; Dimo Dietrich Journal: Clin Epigenetics Date: 2017-12-01 Impact factor: 6.551
Authors: Julia Bergheim; Alexander Semaan; Heidrun Gevensleben; Susanne Groening; Andreas Knoblich; Jörn Dietrich; Julia Weber; Jörg C Kalff; Friedrich Bootz; Glen Kristiansen; Dimo Dietrich Journal: Br J Cancer Date: 2018-04-03 Impact factor: 7.640